Anticoagulation Patents (Class 514/822)
  • Patent number: 10391062
    Abstract: The present invention relates to a dry transglutaminase composition, said composition is obtainable by lyophilizing or spray-drying an aqueous composition comprising a transglutaminase, a salt and at least one further component selected from the group consisting of a sugar, an amino acid, and a buffer, wherein the concentration of the salt in the aqueous composition is in the range from 5 to 100 mM. In further aspects, the present invention relates to a method of preparing said dry transglutaminase composition, a reconstituted solution, a pharmaceutical composition, and method of treatments.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: August 27, 2019
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Mark Brader, Thomas Falck, Gunhild Klarskov Kristiansen
  • Patent number: 10174032
    Abstract: The invention relates to compounds of Formulas I-VII (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating cellular signaling pathways and biological processes associated therewith including inhibition of kinase activity such as PI-3 kinase or inhibition of bromodomain proteins or both at the same time as well as to therapeutic methods for treating a disease associated with aberrant PI3K and/or bromodomain proteins.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: January 8, 2019
    Assignee: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A Morales, Joseph R. Garlich, Kevin T. Weber, Jessica M. Newblom, Donald L. Durden
  • Patent number: 9975903
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
  • Patent number: 9745321
    Abstract: Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: August 29, 2017
    Assignee: SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    Inventor: Zusheng Xu
  • Patent number: 9499561
    Abstract: Disclosed are a fused pyrimidine compound as represented by formula I, pharmaceutically acceptable salt, hydrate and solvate thereof, an optical isomer or a prodrug thereof, as well as a preparation method, an intermediate, a composition and uses thereof. The fused pyrimidine compound according to the present invention can inhibit activity of PI3 kinase, and can be used to treat diseases such as cancer caused by abnormal activity of the PI3 kinase, or can be used to prepare medicine for treating these diseases.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: November 22, 2016
    Assignee: Shanghai Yingli Pharmaceutical Co., Ltd.
    Inventor: Zusheng Xu
  • Patent number: 8404724
    Abstract: Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: March 26, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Stanley J. Hollenbach, Keith Abe
  • Patent number: 8216172
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: July 10, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 8163749
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: April 24, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventor: James R. Corte
  • Patent number: 8158157
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 17, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michael Lannoy
  • Patent number: 8101196
    Abstract: The invention includes a medical hydrogel made from polymerized polysaccharide macromers. The macromers are preferably polysaccharides decorated with polymerizable groups, for example, methacrylates. The macromers may also be made into polymers of at least two macromers polymerized together. These polymers are preferably multi-armed or high-molecular weight and used for medical uses, for example, making coatings on medical devices. Macromers of N-vinylpyrrolidone are also disclosed herein.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: January 24, 2012
    Assignee: BioInteractions, Ltd.
    Inventors: Ajay K. Luthra, Shivpal S. Sandhu, John O. Hudson
  • Patent number: 7758900
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: July 20, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 7655230
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: February 2, 2010
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
  • Patent number: 7557188
    Abstract: Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: July 7, 2009
    Assignee: Baxter Innovations GmbH
    Inventors: Hans-Peter Schwarz, Katalin Varadi, Peter Turecek, Hendrik Coenraad Hemker, Suzette Lucette Beguin
  • Patent number: 7361344
    Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.
    Type: Grant
    Filed: December 28, 2004
    Date of Patent: April 22, 2008
    Assignee: Genentech, Inc.
    Inventors: Martin M. Bednar, Linda Gross, legal representative, G. Roger Thomas, Cordell E. Gross
  • Patent number: 7316911
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 8, 2008
    Assignee: Amgen, Inc.
    Inventor: Christopher F. Toombs
  • Patent number: 7314728
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 1, 2008
    Assignee: Amgen, Inc.
    Inventor: Christopher F. Toombs
  • Patent number: 7294699
    Abstract: The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: November 13, 2007
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Patent number: 7279183
    Abstract: Treatment with magnesium produces a inhibition of acute stent thrombosis under high-shear flow conditions without any hemostatic or significant hemodynamic complications.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: October 9, 2007
    Assignee: Cedars-Sinai Medical Center
    Inventors: Sanjay Kaul, Prediman K. Shah
  • Patent number: 7208180
    Abstract: The present invention relates to a method for the prevention and/or treatment of vascular disorders and/or secondary disorders associated therewith, such as depression. The method according to the invention comprises the oral administration of a preparation which contains at least the following fractions: a) long chain polyunsaturated fatty acids; b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine and c) one or more compounds which are a factor in methionine metabolism, which compounds are selected from the group consisting of folate, vitamin B12, vitamin B6, magnesium and zinc or equivalents thereof. The invention also relates to a preparation for oral dosage comprising: at least 120 mg of long chain polyunsaturated fatty acids; at least 200 mg phospholipids; at least 200 ?g folate; and at least 0.1 mg hypericin and/or at least 100 mg extract of Withania somnifera.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: April 24, 2007
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Patent number: 7208288
    Abstract: Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: April 24, 2007
    Inventors: Joseph P. Broderick, Joseph F. Clark, Daniel Woo
  • Patent number: 7186420
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: March 6, 2007
    Assignee: Edwards Lifesciences Corporation
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 7169573
    Abstract: The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: January 30, 2007
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Shinichiro Kurosawa, Deborah J. Stearns-Kurosawa
  • Patent number: 7033776
    Abstract: A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of ?2-macroglobulin in the circulating blood. A method is also provided for the treatment of a blood clot in, around or attached to an indwelling vascular access device. A method for restoring patency and function of an indwelling vascular access device is also provided.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: April 25, 2006
    Assignee: Amgen Inc.
    Inventor: Christopher F. Toombs
  • Patent number: 7005502
    Abstract: Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: February 28, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Hans-Peter Schwarz, Katalin Varadi, Peter Turecek, Hendrik Coenraad Hemker, Suzette Lucette Beguin
  • Patent number: 6958359
    Abstract: Vanadium compounds for inhibiting angiogenesis useful for treating or preventing diabetic retinopathy, hemangiomas, cancers with abnormal blood vessel supply, restenosis following vascular injury, and the like.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: October 25, 2005
    Assignee: Parker Hughes Institute
    Inventor: Fatih M. Uckun
  • Patent number: 6919374
    Abstract: It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment patients experienced a significant lowering of whole blood viscosity. In vitro addition of APM to patients samples having elevated whole blood viscosity resulted in reduced viscosity over time. These in vivo and in vivo results identify APM as a therapeutic agent for molecular diseases which lead to elevated whole blood viscosity. A method by which APM treatment can be monitored is also disclosed.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: July 19, 2005
    Assignee: Oklahoma Medical Research Foundation
    Inventor: Carl V. Manion
  • Patent number: 6908624
    Abstract: Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: June 21, 2005
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Syed F. A. Hossainy, Steven Z. Wu, Manish Gada, Anthony Andreacchi
  • Patent number: 6878388
    Abstract: Vanadium compounds useful to prevent and/or inhibit adhesion, migration, and invasion of proliferative cells into surrounding tissue.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: April 12, 2005
    Assignee: Parker Hughes Institute
    Inventors: Fatih M Uckun, Rama Krishna Narla
  • Patent number: 6841371
    Abstract: Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins, compared to wild-type protein C and retain the biological activity of the wild-type human protein D. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hyper coagulable states, thrombotic disorders and disease states predisposing to thrombosis.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: January 11, 2005
    Assignee: Eli Lilly and Company
    Inventors: Bruce Edward Gerlitz, Bryan Edward Jones
  • Patent number: 6825323
    Abstract: The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for single or multiple external or internal wounds.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: November 30, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: John R. Hess
  • Publication number: 20040235965
    Abstract: The invention relates to the utilization of rutins and aescins in the treatment of circulatory disturbances of the ear. The invention also relates to agents with a corresponding active ingredient combination and agents in the form of commercial packagings with corresponding combination preparations or monopreparations for combined application.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 25, 2004
    Inventor: Kailash Kumar Gauri
  • Patent number: 6808706
    Abstract: A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized in that the aqueous thrombomodulin solution containing an effective amount of soluble thrombomodulin and a buffer component exhibiting a buffering activity in a pH range of 5 to 7.0 has a pH of 5 to 7.0 and that (a) the aqueous thrombomodulin solution further contains a surfactant and is in a state aseptically filled into a case or (b) the aqueous thrombomodulin solution is the form of a prefilled syringe preparation produced by aseptically filling the thrombomodulin solution into a syringe substantially without any empty space.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: October 26, 2004
    Assignee: Asaki Kasei Pharma Corporation
    Inventors: Masaki Yui, Akira Yokozawa, Tomoyo Murata, Kazuhisa Tsuruta, Hirotomo Shimizu
  • Patent number: 6743191
    Abstract: The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: June 1, 2004
    Assignee: Edwards Lifesciences AG
    Inventor: Pe Chou Chang
  • Patent number: 6645978
    Abstract: Ophthalmic compositions containing Lipoxin A4 and its analogs and methods of their use for treating dry eve are disclosed.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: November 11, 2003
    Assignee: Alcon, Inc.
    Inventors: Daniel A. Gamache, Gustav Graff, Mark R. Hellberg, Peter G. Klimko, John M. Yanni
  • Patent number: 6624289
    Abstract: Novel polypeptides or derivatives comprising the factor VIIIa binding site on factor IXa are disclosed. The novel polypeptides or derivatives have anti-coagulation activity. Nucleic acids encoding those polypeptides are also disclosed. Methods for identifying an agent having anti-coagulation activity are also disclosed. These methods comprise determining whether the agent displaces the polypeptide or derivative from its factor VIIa binding site. The agent identified in these methods is also useful in methods for treating a patient to prevent thrombosis. The treatment methods comprise administration of the agent to the patient. Additional methods are also disclosed for treating a patient to prevent thrombosis, comprising treating the patient with a polypeptide or derivative comprising the factor VIIIa binding site on factor IXa. Methods of preventing coagulation in a blood sample are also disclosed, comprising adding the polypeptides or derivatives described above to the blood sample.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: September 23, 2003
    Assignee: Saint Louis University
    Inventor: S. Paul Bajaj
  • Patent number: 6613897
    Abstract: {circle around (1)} Compounds of the following general formula (1) having a glucuronic acid derivative and a glucosamine derivative in the structure thereof, pharmacologically acceptable salts and solvates of the compounds, or solvates of the salts, {circle around (2)} a method for producing the compounds {circle around (1)}, {circle around (3)} a pharmaceutical composition containing the compounds {circle around (1)}, {circle around (4)} polymers having at least one of the compounds {circle around (1)} as a side chain structure, {circle around (5)} a coating agent containing the compound {circle around (1)} or the polymer as one of active ingredients, and {circle around (6)} molded products, artificial organs, medical devices, and equipment for cell culture, which have been produced using the polymer {circle around (4)} and/or the coating agent {circle around (5)}.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: September 2, 2003
    Assignee: Maruha Corporation
    Inventors: Nobuaki Yatsuka, Nobuyuki Sato, Shigeru Moriyama, Tadakazu Tamai, Masazumi Nishikawa
  • Patent number: 6599881
    Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: July 29, 2003
    Assignee: Xoma Corporation
    Inventors: Mark L. White, William Steve Ammons
  • Patent number: 6559133
    Abstract: A method for treatment of a vascular or cardiovascular condition or acute coronary syndromes comprises administering an effective amount of a flavone 8-carboxylic acid to a mammal suffering from a vascular or cardiovascular condition or acute coronary syndromes. The flavone 8-carboxylic acid is typically flavone 8-acetic acid. The flavone 8-carboxylic acid can be administered alone or in combination with another agent such as a thrombolytic agent, an antithrombotic agent, an anticoagulant, or an antiplatelet agent. The invention also includes pharmaceutical compositions formulated for the treatment of a vascular or cardiovascular condition or acute coronary syndromes.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: May 6, 2003
    Inventor: Jozef S. Mruk
  • Patent number: 6515020
    Abstract: A pharmaceutical product which comprises admixed or separately packaged (A) L-Carnitine or an alkanoyl L-canitine and (B) a trihydroxy- or tetrahydroxystilbene such as resveratrol is useful for the prevention and treatment of pathological neuronal or cerebral disorders.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: February 4, 2003
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Claudio Cavazza
  • Patent number: 6500427
    Abstract: A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof. This adhesive can be reconstituted from a freeze-dried form with water. It can contain aLL active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: December 31, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Norbert Heimburger, Peter Fuhge, Hansjörg Ronneberger
  • Patent number: 6495530
    Abstract: The present invention is directed to a composition comprising a therapeutically effective amount of exogenous heparin and arginine or physiologically acceptable salts thereof which is used in the treatment and prevention of cardiovascular diseases or disorders.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: December 17, 2002
    Assignee: Endomatrix, Inc.
    Inventor: Bruce A. Daniels
  • Patent number: 6486205
    Abstract: A new natural mixture of primary fatty acids of high molecular weight ranging from 24 to 38 carbon atoms, especially those ranging between 26 and 36 carbon atoms and more especially those of straight chain of 26, 28, 29, 30, 31, 32, 33, 34, 35 and 36 carbon atoms. This mixture has a relative composition of each fatty acid that is highly reproducible batch to batch and it is extracted from sugar cane (Saccharum officinarum, L.) wax. This mixture of fatty acids has specific pharmacological properties that supports its use as an active component of pharmaceutical formulations used as hypocholesterolemic and against hypercholesterolaemia type II, as antiplatelet, anti-thrombotic and anti-ischemic. This mixture of primary fatty acids is also effective in the inhibition of the development of gastric ulcers induced by different agents.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: November 26, 2002
    Assignee: Laboratorios Dalmer SA
    Inventors: Luis Gonzáles Bravo, David Marrero Delange, Abilo Laguna Granja, Rosa Maria Más Ferreiro, Maria de Lourdes Arruzazabala Valmana, Daysi Carbajal Quintana, Mirian Cora Medina, Roberto Menendez Soto del Valle
  • Patent number: 6461640
    Abstract: A method of preventing adhesions by topical administration of fibrinolysis enhancing agents is described. The method uses a topically applied polymeric matrix for delivery of a fibrinolytic agent, preferably urokinase, tPA, hirudin, or most preferably, ancrod. In the most preferred embodiment, the matrix is extremely thin and is polymerized in situ to form a biodegradable polymeric matrix. The matrix provides controlled release of the agent over a period of time effective to prevent surgical adhesions and is biodegradable, usually within the same time frame. Examples demonstrate that the combination of the matrix and the urokinase, tPA, hirudin, or ancrod is effective in preventing surgical adhesions.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: October 8, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jeffrey A. Hubbell, Jennifer L. Hill-West, Randall C. Dunn
  • Patent number: 6436367
    Abstract: A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation.
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: August 20, 2002
    Assignee: Generex Pharmaceuticals Inc.
    Inventor: Pankaj Modi
  • Patent number: 6423334
    Abstract: A composition for enteral administration having a non-ionic vegetable oil GIT absorption enhancer capable of increasing the enteral absorbability of drugs, especially oral absorbability of hydrophilic and macromolecular drugs. The non-ionic vegetable oil GIT absorption enhancer, particularly Babassu oil or a derivative thereof, is capable of enhancing the uptake of a drug from the gastrointestinal tract so as to allow therapeutically effective amounts of the drug to be transported across the GIT of an animal such as a human without significant toxic side effects.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: July 23, 2002
    Assignee: Elan Corporation, plc
    Inventors: David J. Brayden, Jacqueline M. Dee
  • Patent number: 6423348
    Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: July 23, 2002
    Inventor: James C. Mickus
  • Patent number: 6413931
    Abstract: A method of inhibiting fibrin clot formation is provided. The decorin protein, peptide, or related fragments are found to bind fibrinogen in the presence of Zinc (Zn2+), thus preventing the formation of fibrin clots. The decorin protein, peptide, or related fragments can be utilized as an anticoagulant and in methods of preventing and/or treating diseases and disorders characterized by clot formation.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: July 2, 2002
    Assignee: The Texas A&M University System
    Inventors: Magnus A. H{umlaut over (oo)}k, Vivian W-C Yang
  • Patent number: 6399624
    Abstract: A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer are applied to the injured areas subsequent to surgical injury.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: June 4, 2002
    Assignee: MDV Technologies, Inc.
    Inventors: Lorraine E. Reeve, Stephen G. Flore
  • Patent number: 6391339
    Abstract: The invention relates to the use of a certain oligosaccharide for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: May 21, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Jacobus Christianus Johannes Stiekema, Jean Marc Herbert
  • Patent number: 6387360
    Abstract: An anti-jaundice composition for providing coloration to a corpse, comprising a bleaching agent, a coloring agent, and a fixing agent, mixed and stored at room temperature, and administered internally to a corpse for providing uniform, controlled coloration of the skin and tissue and for preventing tissue degradation. The invention is also directed to a method for providing an anti-jaundice composition for providing coloration to a corpse.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 14, 2002
    Inventor: Kurt Anthony Garrett